' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy.
Moser, T; OSullivan, C; Puttinger, C; Feige, J; Pilz, G; Haschke-Becher, E; Cadamuro, J; Oberkofler, H; Hitzl, W; Harrer, A; Kraus, J; Trinka, E; Wipfler, P;
Biomedicines. 2021; 9(11):
Originalarbeiten (Zeitschrift)


Cadamuro Janne
Feige Julia
Harrer Andrea
Haschke-Becher Elisabeth
Hitzl Wolfgang
Kraus Jörg
Moser Tobias
Oberkofler Hannes
Pilz Georg
Trinka Eugen
Wipfler Peter


Cladribine (CLAD) is a lymphodepleting agent approved for active relapsing multiple sclerosis (MS). The impact of CLAD on the adaptive humoral immune system has not sufficiently been studied. This study aimed to assess the influence of CLAD treatment on specific antibody titers to common pathogens. We included 18 MS patients treated with CLAD. Serum IgG antibody levels to measles, mumps, rubella, hepatitis B and varicella zoster virus (VZV), as well as diphtheria and tetanus toxins, were measured prior to the initiation of treatment and at 12 and 24 months after first CLAD administration. Moreover, specimens were longitudinally analyzed regarding absolute blood concentrations of IgG and main lymphocyte subsets. No reduction in antibody levels against measles, mumps, rubella, VZV, hepatitis B, diphtheria toxin and tetanus toxin associated with CLAD treatment was observed. Loss of seroprotection occurred in <1%. We found no significant impact of CLAD on absolute serum IgG levels. Absolute lymphocyte counts were significantly reduced at the end of each treatment year (

Find related publications in this database (Keywords)

immune reconstitution
antibody levels